Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ADMA ADMA Biologics	$16.73 -4.9%	$19.22	$10.21 ▼ $25.67	$4.20B	0.43	3.66 million shs	3.84 million shs
CRSP CRISPR Therapeutics	$65.13 +18.2%	$44.67	$30.04 ▼ $66.10	$4.76B	1.82	1.99 million shs	10.16 million shs
HROW Harrow	$35.89 -0.7%	$30.13	$20.85 ▼ $59.23	$1.33B	0.41	500,180 shs	482,017 shs
RYTM Rhythm Pharmaceuticals	$89.20 -1.6%	$67.14	$40.61 ▼ $94.80	$5.77B	2.26	590,318 shs	624,068 shs

7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google

Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ADMA ADMA Biologics	-0.57%	-4.76%	-6.88%	-17.46%	+32.36%
CRSP CRISPR Therapeutics	-0.09%	-6.63%	+27.55%	+45.86%	-8.91%
HROW Harrow	+4.60%	+15.21%	+18.84%	+50.65%	+43.70%
RYTM Rhythm Pharmaceuticals	-0.83%	+1.84%	+46.33%	+46.87%	+74.12%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ADMA ADMA Biologics	3.8794 of 5 stars	3.7	1.0	0.0	2.9	2.5	3.1
CRSP CRISPR Therapeutics	2.69 of 5 stars	3.3	1.0	0.0	3.3	3.3	0.6
HROW Harrow	2.3739 of 5 stars	3.5	1.0	0.0	2.4	2.5	0.6
RYTM Rhythm Pharmaceuticals	3.1928 of 5 stars	2.5	1.0	4.3	2.6	0.8	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ADMA ADMA Biologics	3.33	Buy	$27.67	65.37% Upside
CRSP CRISPR Therapeutics	2.53	Moderate Buy	$71.75	10.16% Upside
HROW Harrow	3.00	Buy	$63.83	77.86% Upside
RYTM Rhythm Pharmaceuticals	3.07	Buy	$91.93	3.06% Upside

Current Analyst Ratings Breakdown

Latest HROW, CRSP, ADMA, and RYTM Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/18/2025	RYTM Rhythm Pharmaceuticals	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$92.00 ➝ $105.00
7/11/2025	HROW Harrow	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$76.00
7/10/2025	RYTM Rhythm Pharmaceuticals	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
7/10/2025	RYTM Rhythm Pharmaceuticals	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Outperform ➝ Outperform	$76.00 ➝ $110.00
7/10/2025	RYTM Rhythm Pharmaceuticals	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$73.00 ➝ $95.00
7/10/2025	RYTM Rhythm Pharmaceuticals	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$91.00 ➝ $129.00
7/10/2025	RYTM Rhythm Pharmaceuticals	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$97.00
7/9/2025	RYTM Rhythm Pharmaceuticals	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Overweight ➝ Overweight	$95.00
7/9/2025	RYTM Rhythm Pharmaceuticals	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$72.00 ➝ $95.00
7/8/2025	CRSP CRISPR Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$81.00
7/7/2025	RYTM Rhythm Pharmaceuticals	Leerink Partnrs Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy

(Data available from 7/18/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ADMA ADMA Biologics	$426.45M	9.37	$0.51 per share	32.50	$1.48 per share	11.30
CRSP CRISPR Therapeutics	$37.31M	150.75	N/A	N/A	$22.64 per share	2.88
HROW Harrow	$199.61M	6.60	$0.14 per share	264.30	$1.95 per share	18.41
RYTM Rhythm Pharmaceuticals	$130.13M	43.61	N/A	N/A	$0.35 per share	254.86

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ADMA ADMA Biologics	$197.67M	$0.85	19.68	24.25	N/A	45.01%	47.16%	30.51%	8/6/2025 (Estimated)
CRSP CRISPR Therapeutics	-$366.25M	-$4.52	N/A	N/A	N/A	-1,023.64%	-20.08%	-17.13%	8/4/2025 (Estimated)
HROW Harrow	-$17.48M	-$0.56	N/A	89.73	N/A	-10.19%	-25.01%	-4.27%	8/6/2025 (Estimated)
RYTM Rhythm Pharmaceuticals	-$260.60M	-$2.81	N/A	N/A	N/A	-123.26%	-739.62%	-44.27%	8/5/2025 (Estimated)

Latest HROW, CRSP, ADMA, and RYTM Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2025	Q2 2025	ADMA ADMA Biologics	$0.14	N/A	N/A	N/A	N/A	N/A
8/6/2025	Q2 2025	HROW Harrow	$0.01	N/A	N/A	N/A	$64.23 million	N/A
8/5/2025	Q2 2025	RYTM Rhythm Pharmaceuticals	-$0.64	N/A	N/A	N/A	$43.72 million	N/A
8/4/2025	Q2 2025	CRSP CRISPR Therapeutics	-$1.54	N/A	N/A	N/A	$6.44 million	N/A
5/8/2025	Q1 2025	HROW Harrow	$0.02	-$0.38	-$0.40	-$0.50	$57.00 million	$47.83 million
5/7/2025	Q1 2025	ADMA ADMA Biologics	$0.16	$0.14	-$0.02	$0.11	$116.40 million	$114.80 million
5/7/2025	Q1 2025	RYTM Rhythm Pharmaceuticals	-$0.69	-$0.81	-$0.12	-$0.81	$40.43 million	$37.72 million
5/6/2025	Q1 2025	CRSP CRISPR Therapeutics	-$1.27	-$1.58	-$0.31	-$1.58	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ADMA ADMA Biologics	N/A	N/A	N/A	N/A	N/A
CRSP CRISPR Therapeutics	N/A	N/A	N/A	N/A	N/A
HROW Harrow	N/A	N/A	N/A	N/A	N/A
RYTM Rhythm Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ADMA ADMA Biologics	0.22	6.58	3.36
CRSP CRISPR Therapeutics	N/A	15.64	15.64
HROW Harrow	2.01	0.91	0.85
RYTM Rhythm Pharmaceuticals	N/A	3.30	3.13

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ADMA ADMA Biologics	75.68%
CRSP CRISPR Therapeutics	69.20%
HROW Harrow	72.76%
RYTM Rhythm Pharmaceuticals	N/A

Insider Ownership

Company	Insider Ownership
ADMA ADMA Biologics	3.50%
CRSP CRISPR Therapeutics	4.30%
HROW Harrow	15.16%
RYTM Rhythm Pharmaceuticals	6.10%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ADMA ADMA Biologics	530	238.73 million	230.38 million	Optionable
CRSP CRISPR Therapeutics	460	86.36 million	82.65 million	Optionable
HROW Harrow	180	36.69 million	31.12 million	Optionable
RYTM Rhythm Pharmaceuticals	140	63.62 million	59.74 million	Optionable

HROW, CRSP, ADMA, and RYTM Headlines

Recent News About These Companies

Rhythm Pharmaceuticals CFO Sells 42,120 Shares

4 hours ago | msn.com

Rhythm Pharmaceuticals (NASDAQ:RYTM) Given New $105.00 Price Target at Canaccord Genuity Group

July 18 at 10:31 AM | marketbeat.com

Q2 Earnings Estimate for RYTM Issued By Leerink Partnrs

July 16 at 6:25 AM | marketbeat.com

Analysts Set Expectations for RYTM Q4 Earnings

July 15 at 8:23 AM | marketbeat.com

Q2 EPS Estimate for Rhythm Pharmaceuticals Lifted by Analyst

July 15 at 2:12 AM | americanbankingnews.com

Leo Wealth LLC Purchases New Shares in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM)

July 14, 2025 | marketbeat.com

Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) CFO Sells $3,389,817.60 in Stock

July 14, 2025 | americanbankingnews.com

Insider Selling: Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Insider Sells 15,572 Shares of Stock

July 14, 2025 | americanbankingnews.com

Leerink Partnrs Issues Optimistic Outlook for RYTM Earnings

July 14, 2025 | marketbeat.com

Alps Advisors Inc. Has $2.45 Million Stock Holdings in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM)

July 13, 2025 | marketbeat.com

Bank of America Issues Positive Forecast for Rhythm Pharmaceuticals (NASDAQ:RYTM) Stock Price

July 13, 2025 | americanbankingnews.com

Wells Fargo & Company Issues Positive Forecast for Rhythm Pharmaceuticals (NASDAQ:RYTM) Stock Price

July 13, 2025 | americanbankingnews.com

The Goldman Sachs Group Begins Coverage on Rhythm Pharmaceuticals (NASDAQ:RYTM)

July 13, 2025 | americanbankingnews.com

Oppenheimer Forecasts Strong Price Appreciation for Rhythm Pharmaceuticals (NASDAQ:RYTM) Stock

July 13, 2025 | americanbankingnews.com

Rhythm Pharmaceuticals Presents Data on MC4R Agonists Setmelanotide and Bivamelagon at ENDO 2025

July 12, 2025 | globenewswire.com

Rhythm Pharmaceuticals (RYTM) Stock Jumps 36.6%: Will It ... - Nasdaq

July 12, 2025 | nasdaq.com

Insider Selling: Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) CAO Sells 3,817 Shares of Stock

July 12, 2025 | insidertrades.com

Q2 Earnings Forecast for RYTM Issued By Leerink Partnrs

July 12, 2025 | americanbankingnews.com

Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) CAO Christopher Paul German Sells 3,817 Shares

July 11, 2025 | marketbeat.com

Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Insider Sells $619,828.82 in Stock

July 11, 2025 | marketbeat.com

Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Insider Pamela J. Cramer Sells 15,572 Shares

July 11, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

HROW, CRSP, ADMA, and RYTM Company Descriptions

ADMA Biologics NASDAQ:ADMA

$16.73 -0.86 (-4.89%)

Closing price 04:00 PM Eastern

Extended Trading

$17.12 +0.39 (+2.33%)

As of 07:55 PM Eastern

ADMA Biologics, Inc., a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. It develops a pipeline of plasma-derived therapeutics, including products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, it operates source plasma collection facilities. The company sells its products through independent distributors, drug wholesalers, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was incorporated in 2004 and is headquartered in Ramsey, New Jersey.

CRISPR Therapeutics NASDAQ:CRSP

$65.13 +10.04 (+18.22%)

Closing price 04:00 PM Eastern

Extended Trading

$64.90 -0.23 (-0.35%)

As of 07:59 PM Eastern

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases. To accelerate and expand its efforts, CRISPR Therapeutics has established strategic collaborations with companies including Bayer, Vertex Pharmaceuticals and ViaCyte, Inc. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Cambridge, Massachusetts, and business offices in San Francisco, California and London, United Kingdom. For more information, please visit www.crisprtx.com.

Harrow NASDAQ:HROW

$35.89 -0.25 (-0.69%)

Closing price 04:00 PM Eastern

Extended Trading

$36.60 +0.70 (+1.96%)

As of 06:34 PM Eastern

Harrow, Inc. operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. The company was formerly known as Imprimis Pharmaceuticals, Inc. and changed its name to Harrow Health, Inc. in December 2018. Harrow Health, Inc. was incorporated in 2006 and is headquartered in Nashville, Tennessee.

Rhythm Pharmaceuticals NASDAQ:RYTM

$89.20 -1.48 (-1.63%)

Closing price 04:00 PM Eastern

Extended Trading

$90.39 +1.19 (+1.33%)

As of 07:55 PM Eastern

Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome. It is in Phase 3 clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid receptor coactivator 1 deficiency obesity, SH2B1 deficiency obesity, MC4 receptor deficiency obesity, and other MC4R disorders. The company has licensing agreements with LG Chem, Ltd; Ipsen Pharma S.A.S; Camurus; RareStone Group Ltd.; and LG Chem, Ltd. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. Rhythm Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time